These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 16996282)

  • 1. Pharmacophore identification and virtual screening for methionyl-tRNA synthetase inhibitors.
    Bharatham N; Bharatham K; Lee KW
    J Mol Graph Model; 2007 Mar; 25(6):813-23. PubMed ID: 16996282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacophore-based virtual screening: the discovery of novel methionyl-tRNA synthetase inhibitors.
    Kim SY; Lee YS; Kang T; Kim S; Lee J
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4898-907. PubMed ID: 16824759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel inhibitors of methionyl-tRNA synthetase (MetRS) by virtual screening.
    Finn J; Stidham M; Hilgers M; G C K
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3932-7. PubMed ID: 18590962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore mapping of diverse classes of farnesyltransferase inhibitors.
    Equbal T; Silakari O; Rambabu G; Ravikumar M
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1594-600. PubMed ID: 17236767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methionyl-tRNA synthetase.
    Deniziak MA; Barciszewski J
    Acta Biochim Pol; 2001; 48(2):337-50. PubMed ID: 11732605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure modeling, ligand binding, and binding affinity calculation (LR-MM-PBSA) of human heparanase for inhibition and drug design.
    Zhou Z; Bates M; Madura JD
    Proteins; 2006 Nov; 65(3):580-92. PubMed ID: 16972282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyltransferase pharmacophore model derived from diverse classes of inhibitors.
    Lu A; Zhang J; Yin X; Luo X; Jiang H
    Bioorg Med Chem Lett; 2007 Jan; 17(1):243-9. PubMed ID: 17049856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First pharmacophore model of CCR3 receptor antagonists and its homology model-assisted, stepwise virtual screening.
    Jain V; Saravanan P; Arvind A; Mohan CG
    Chem Biol Drug Des; 2011 May; 77(5):373-87. PubMed ID: 21284830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definition of the heterocyclic pharmacophore of bacterial methionyl tRNA synthetase inhibitors: potent antibacterially active non-quinolone analogues.
    Jarvest RL; Armstrong SA; Berge JM; Brown P; Elder JS; Brown MJ; Copley RC; Forrest AK; Hamprecht DW; O'Hanlon PJ; Mitchell DJ; Rittenhouse S; Witty DR
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3937-41. PubMed ID: 15225702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding mode analyses and pharmacophore model development for sulfonamide chalcone derivatives, a new class of alpha-glucosidase inhibitors.
    Bharatham K; Bharatham N; Park KH; Lee KW
    J Mol Graph Model; 2008 Jun; 26(8):1202-12. PubMed ID: 18096420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent and selective inhibitors of bacterial methionyl tRNA synthetase derived from an oxazolone-dipeptide scaffold.
    Tandon M; Coffen DL; Gallant P; Keith D; Ashwell MA
    Bioorg Med Chem Lett; 2004 Apr; 14(8):1909-11. PubMed ID: 15050625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of quinolinones as methionyl-tRNA synthetase inhibitors.
    Farhanullah ; Kim SY; Yoon EJ; Choi EC; Kim S; Kang T; Samrin F; Puri S; Lee J
    Bioorg Med Chem; 2006 Nov; 14(21):7154-9. PubMed ID: 16854585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.
    Aparoy P; Kumar Reddy K; Kalangi SK; Chandramohan Reddy T; Reddanna P
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1013-8. PubMed ID: 20045317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.
    Li HF; Lu T; Zhu T; Jiang YJ; Rao SS; Hu LY; Xin BT; Chen YD
    Eur J Med Chem; 2009 Mar; 44(3):1240-9. PubMed ID: 18947905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors.
    Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK
    Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel hybrid virtual screening protocol based on molecular docking and structure-based pharmacophore for discovery of methionyl-tRNA synthetase inhibitors as antibacterial agents.
    Liu C; He G; Jiang Q; Han B; Peng C
    Int J Mol Sci; 2013 Jul; 14(7):14225-39. PubMed ID: 23839093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.
    Parenti MD; Pacchioni S; Ferrari AM; Rastelli G
    J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling ligand-receptor interaction for some MHC class II HLA-DR4 peptide mimetic inhibitors using several molecular docking and 3D QSAR techniques.
    Wei HY; Tsai KC; Lin TH
    J Chem Inf Model; 2005; 45(5):1343-51. PubMed ID: 16180911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuraminidase pharmacophore model derived from diverse classes of inhibitors.
    Zhang J; Yu K; Zhu W; Jiang H
    Bioorg Med Chem Lett; 2006 Jun; 16(11):3009-14. PubMed ID: 16530411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
    Yu H; Wang Z; Zhang L; Zhang J; Huang Q
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.